Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by bfwon May 25, 2018 1:02pm

218 Views

Post# 28081456

RE:Egrifta sales Pop

SPCEO1 wrote: Bloomberg reported Egrifta sales for the latest week of 250 prescriptions, the highest weekly level since 2013. So, it appears Trogarzo is having a clear beneficial impact on Egrifta as well. With ADAP now added to the equation, we may see another bump higher in future weeks.

It is only good news recently for TH.

Yes, I spoke about the synergy many moons ago.

TH reps now have an audience for two HIV drugs. More docs are willing to talk to them based on the necessity of getting some patients on Trogarzo.

The extra face time allows them to detail Egrifta as well.

Win win situation :)

bfw

Bullboard Posts

How one company is disrupting PoC testing